The DOI matches its Crossref record; 81 of the 81 references it cites were found in a registry or an index.
A systematic review of the antipsychotic properties of cannabidiol in humans
Open accessAbstract
Despite extensive study over the past decades, available treatments for schizophrenia are only modestly effective and cause serious metabolic and neurological side effects. Therefore, there is an urgent need for novel therapeutic targets for the treatment of schizophrenia. A highly promising new pharmacological target in the context of schizophrenia is the endocannabinoid system. Modulation of this system by the main psychoactive component in cannabis, Δ9-tetrahydrocannabinol (THC), induces acute psychotic effects and cognitive impairment. However, the non-psychotropic, plant-derived cannabinoid agent cannabidiol (CBD) may have antipsychotic properties, and thus may be a promising new agent in the treatment of schizophrenia. Here we review studies that investigated the antipsychotic properties of CBD in human subjects. Results show the ability of CBD to counteract psychotic symptoms and cognitive impairment associated with cannabis use as well as with acute THC administration. In addition, CBD may lower the risk for developing psychosis that is related to cannabis use. These effects are possibly mediated by opposite effects of CBD and THC on brain activity patterns in key regions implicated in the pathophysiology of schizophrenia, such as the striatum, hippocampus and prefrontal cortex. The first small-scale clinical studies with CBD treatment of patients with psychotic symptoms further confirm the potential of CBD as an effective, safe and well-tolerated antipsychotic compound, although large randomised clinical trials will be needed before this novel therapy can be introduced into clinical practice.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The protective role that CBD could play to alleviate these negative effects is now well established and documented (Iseger and Bossong, 2015).”
From Cannabis sativa: The Plant of the Thousand and One Molecules (2016) · cites this paper as Iseger and Bossong, 2015
In the citing paper
“A number of studies indicate that cannabis strains containing higher THC:CBD ratios may result in greater risk of psychotic outcomes, and that CBD might have anti-psychotic properties (27)(28)(29)47).”
From Association Between Cannabis and Psychosis: Epidemiologic Evidence (2016) · cites this paper as [29]
Citations
Cites
Ledent, C. A., Valverde, O., Cossu, G., Petitet, F., Aubert, J.-F., Beslot, F., Böhme, G. A., Impérato, A., Pedrazzini, T., Roques, B. P., et al. (1999) · Science · doi:10.1126/science.283.5400.401 · Cited by 3,628
Schizophrenia: A Concise Overview of Incidence, Prevalence, and Mortality
McGrath, J., Saha, S., Chant, D., & Welham, J. (2008) · Epidemiologic Reviews · doi:10.1093/epirev/mxn001 · Cited by 2,280
Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review.
Moore, T. H., Zammit, S., Lingford-Hughes, A., Barnes, T. R., Jones, P. B., Burke, M., & Lewis, G. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61162-3 · Cited by 2,224
Herkenham, M., Lynn, A., Johnson, M., Melvin, L., de Costa, B., & Rice, K. (1991) · The Journal of Neuroscience · doi:10.1523/jneurosci.11-02-00563.1991 · Cited by 2,159
Pertwee, R. G. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707442 · Cited by 2,047
van Os, J., & Kapur, S. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60995-8 · Cited by 1,971
Endocannabinoid-Mediated Control of Synaptic Transmission
Kano, M., Ohno‐Shosaku, T., Hashimotodani, Y., Uchigashima, M., & Watanabe, M. (2009) · Physiological Reviews · doi:10.1152/physrev.00019.2008 · Cited by 1,595
Bisogno, T., Hanuš, L., PETROCELLIS, L. D., Tchilibon, S., Ponde, D. E., Brandi, I., Moriello, A. S., Davis, J. B., Mechoulam, R., & Marzo, V. D. (2001) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0704327 · Cited by 1,315
Schizophrenia, “just the facts” 4. Clinical features and conceptualization
Tandon, R., Nasrallah, H. A., & Keshavan, M. S. (2009) · Schizophrenia Research · doi:10.1016/j.schres.2009.03.005 · Cited by 1,101
Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia
Leweke, F. M., Piomelli, D., Pahlisch, F., Muhl, D., Gerth, C. W., Hoyer, C., Klosterkötter, J., Hellmich, M., & Koethe, D. (2012) · Translational Psychiatry · doi:10.1038/tp.2012.15 · Cited by 1,059
Research works printed but not linked: 1
- Zuardi, 1984, Pharmacological interaction between 9-tetrahydrocannabinol and cannabidiol, two active constituents of Cannabis sativa, Ciênc. Cult., 36, 386
Cited by
Sorted by citations
Cannabis sativa: The Plant of the Thousand and One Molecules
Andre, C. M., Hausman, J.-F., & Guerriero, G. (2016) · Frontiers in Plant Science · doi:10.3389/fpls.2016.00019 · Cited by 1,544
“The protective role that CBD could play to alleviate these negative effects is now well established and documented (Iseger and Bossong, 2015).”
BackgroundIffland, K., & Grotenhermen, F. (2017) · Cannabis & Cannabinoid Research · doi:10.1089/can.2016.0034 · Cited by 645
Cannabidiol: State of the art and new challenges for therapeutic applications
Pisanti, S., Malfitano, A. M., Ciaglia, E., Lamberti, A., Ranieri, R., Cuomo, G., Abate, M., Faggiana, G., Proto, M., Fiore, D., et al. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.02.041 · Cited by 664
Mikulska, J., Juszczyk, G., Gawrońska-Grzywacz, M., & Herbet, M. (2021) · Brain Sciences · doi:10.3390/brainsci11101298 · Cited by 450
Lower-Risk Cannabis Use Guidelines: A Comprehensive Update of Evidence and Recommendations
Fischer, B., Russell, C., Sabioni, P., van den Brink, W., Foll, B. L., Hall, W., Rehm, J. T., & Room, R. (2017) · American Journal of Public Health · doi:10.2105/ajph.2017.303818 · Cited by 474
Association Between Cannabis and Psychosis: Epidemiologic Evidence
Gage, S. H., Hickman, M., & Zammit, S. (2016) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.08.001 · Cited by 379
Cannabinoids and Pain: New Insights From Old Molecules
Vučković, S., Srebro, D., Vujović, K. S., Vučetić, Č., & Prostran, M. S. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01259 · Cited by 440
García-Gutiérrez, M. S., Navarrete, F., Gasparyan, A., Austrich-Olivares, A., Sala, F., & Manzanares, J. (2020) · Biomolecules · doi:10.3390/biom10111575 · Cited by 306
Cannabis and mental illness: a review
Lowe, D. J. E., Sasiadek, J., Coles, A. S., & George, T. P. (2018) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-018-0970-7 · Cited by 282
Medical cannabis and mental health: A guided systematic review
Walsh, Z., González, R., Crosby, K., Thiessen, M. S., Carroll, C., & Bonn‐Miller, M. O. (2016) · Clinical Psychology Review · doi:10.1016/j.cpr.2016.10.002 · Cited by 260
Boggs, D. L., Nguyen, J. D., Morgenson, D., Taffe, M. A., & Ranganathan, M. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2017.209 · Cited by 250
Cannabis, cannabinoids, and health
Lafaye, G., Karila, L., Blecha, L., & Benyamina, A. (2017) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2017.19.3/glafaye · Cited by 238
Ferber, S. G., Namdar, D., Hen-Shoval, D., Eger, G., Koltai, H., Shoval, G., Shbiro, L., & Weller, A. (2019) · Current Neuropharmacology · doi:10.2174/1570159x17666190903103923 · Cited by 239
Freeman, A. M., Petrilli, K., Lees, R., Hindocha, C., Mokrysz, C., Curran, H. V., Saunders, R., & Freeman, T. P. (2019) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2019.09.036 · Cited by 232
Iversen, L. L. (2007) · Oxford University Press eBooks · doi:10.1093/acprof:oso/9780195328240.001.0001 · Cited by 230
Gage, S. H., Jones, H. J., Burgess, S., Bowden, J., Smith, G. D., Zammit, S., & Munafo, M. R. (2016) · Psychological Medicine · doi:10.1017/s0033291716003172 · Cited by 219
Cohen, K., & Weinstein, A. M. (2018) · Frontiers in Public Health · doi:10.3389/fpubh.2018.00162 · Cited by 209
Hurd, Y. L., Yoon, M. J., Manini, A. F., Hernandez, S. H., Olmedo, R., Östman, M., & Jutras‐Aswad, D. (2015) · Neurotherapeutics · doi:10.1007/s13311-015-0373-7 · Cited by 171
Lim, K., See, Y. M., & Lee, J. (2017) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2017.15.4.301 · Cited by 166
A systematic review of the effect of cannabidiol on cognitive function: Relevance to schizophrenia
Osborne, A. L., Solowij, N., & Weston–Green, K. (2016) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.11.012 · Cited by 154
Bhattacharyya, S., Wilson, R., Appiah-Kusi, E., O'Neill, A., Brammer, M., Perez, J., Murray, R., Allen, P., Bossong, M., & McGuire, P. (2018) · JAMA psychiatry · doi:10.1001/jamapsychiatry.2018.2309 · Cited by 134
Self-citationTherapeutic potential of cannabis-related drugs
Alexander, S. P. H. (2016) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2015.07.001 · Cited by 149
Golombek, P., Müller, M., Barthlott, I., Sproll, C., & Lachenmeier, D. W. (2020) · Toxics · doi:10.3390/toxics8020041 · Cited by 137
Cohen, K., & Weinstein, A. M. (2018) · Brain Sciences · doi:10.3390/brainsci8030040 · Cited by 136
Cannabinoids, Blood–Brain Barrier, and Brain Disposition
Calapai, F., Cardia, L., Sorbara, E. E., Navarra, M., Gangemi, S., Calapai, G., & Mannucci, C. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12030265 · Cited by 139
Safety and Toxicology of Cannabinoids
Sachs, J., McGlade, E., & Yurgelun-Todd, D. A. (2015) · Neurotherapeutics · doi:10.1007/s13311-015-0380-8 · Cited by 134
Fleury-Teixeira, P., Caixeta, F. V., da Silva, L. C. R., Brasil-Neto, J. P., & Malcher‐Lopes, R. (2019) · Frontiers in Neurology · doi:10.3389/fneur.2019.01145 · Cited by 140
Human Laboratory Studies on Cannabinoids and Psychosis
Sherif, M. A., Radhakrishnan, R., D’Souza, D. C., & Ranganathan, M. (2016) · Biological Psychiatry · doi:10.1016/j.biopsych.2016.01.011 · Cited by 129
Cannabinoids: Medical implications
Schrot, R. J., & Hubbard, J. R. (2016) · Annals of Medicine · doi:10.3109/07853890.2016.1145794 · Cited by 135
Kaur, G., & Kander, R. (2023) · Sustainability · doi:10.3390/su15086457 · Cited by 127
Toth, J. A., Stack, G. M., Cala, A. R., Carlson, C. H., Wilk, R. L., Crawford, J. L., Viands, D. R., Philippe, G., Smart, C. D., Rose, J. K. C., et al. (2020) · GCB Bioenergy · doi:10.1111/gcbb.12667 · Cited by 115
Self‐initiated use of topical cannabidiol oil for epidermolysis bullosa
Chelliah, M. P., Zinn, Z. A., Khuu, P., & Teng, J. M. C. (2018) · Pediatric Dermatology · doi:10.1111/pde.13545 · Cited by 114
Use and Perceptions of Cannabidiol Products in Canada and in the United States
Goodman, S. E., Wadsworth, E., Schauer, G. L., & Hammond, D. G. (2020) · Cannabis and Cannabinoid Research · doi:10.1089/can.2020.0093 · Cited by 111
Psychiatric comorbidity associated with synthetic cannabinoid use compared to cannabis
Nia, A. B., Medrano, B., Perkel, C., GALYNKER, I. I., & Hurd, Y. L. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116658990 · Cited by 107
Demographic and clinical correlates of substance use disorders in first episode psychosis
Brunette, M. F., Mueser, K. T., Babbin, S. F., Meyer-Kalos, P., Rosenheck, R. A., Correll, C. U., Cather, C., Robinson, D. G., Schooler, N. R., Penn, D. L., et al. (2017) · Schizophrenia Research · doi:10.1016/j.schres.2017.06.039 · Cited by 101
Cannabis use in Europe: Current trends and public health concerns
Manthey, J. (2019) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2019.03.006 · Cited by 94
Silote, G. P., Sartim, A. G., Sales, A. J., Eskelund, A., Guimarães, F. S., Wegener, G., & Joca, S. R. L. (2019) · Journal of Chemical Neuroanatomy · doi:10.1016/j.jchemneu.2019.04.006 · Cited by 98
Appiah‐Kusi, E., Petros, N., Wilson, R. J., Colizzi, M., Bossong, M. G., Valmaggia, L., Mondelli, V., McGuire, P. K., & Bhattacharyya, S. (2020) · Psychopharmacology · doi:10.1007/s00213-019-05442-6 · Cited by 93
Self-citationMedical cannabis ‒ the Canadian perspective
Ramkellawan, S., Bober, S., Mindra, S., Moreau, J. M., & Ko, G. D. (2016) · Journal of Pain Research · doi:10.2147/jpr.s98182 · Cited by 91
Modulatory effects of cannabinoids on brain neurotransmission
Cohen, K., Weizman, A., & Weinstein, A. M. (2019) · European Journal of Neuroscience · doi:10.1111/ejn.14407 · Cited by 98
Alpár, A., Marzo, V. D., & Harkany, T. (2015) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.09.009 · Cited by 94
Cannabis and development of dual diagnoses: A literature review
Hanna, R. C., Perez, J. M., & Ghose, S. (2016) · The American Journal of Drug and Alcohol Abuse · doi:10.1080/00952990.2016.1213273 · Cited by 93
Animal models of gene–environment interaction in schizophrenia: A dimensional perspective
Ayhan, Y., McFarland, R., & Pletnikov, M. V. (2015) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2015.10.002 · Cited by 82
Večeřa, J., Bártová, E., Krejčí, J., Legartová, S., Komůrková, D., Kučerová, J., Štark, T., Dražanová, E., Kašpárek, T., Šulcová, A., et al. (2017) · Journal of Cellular Physiology · doi:10.1002/jcp.25914 · Cited by 80
Cannabis and Endocannabinoid Signaling in Epilepsy
Katona, I. (2015) · Handbook of experimental pharmacology · doi:10.1007/978-3-319-20825-1_10 · Cited by 86
Batalla, A., Janssen, H., Gangadin, S. S., & Bossong, M. G. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8071058 · Cited by 79
Self-citationCannabidiol Prevents Motor and Cognitive Impairments Induced by Reserpine in Rats
Peres, F. F., Levin, R. R., Suiama, M. A., Diana, M. C., Gouvêa, D. A., de Almeida, V., Santos, C. M., Lungato, L., Zuardi, A. W., Hallak, J. E. C., et al. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00343 · Cited by 79
Prolonged Cannabidiol Treatment Effects on Hippocampal Subfield Volumes in Current Cannabis Users
Beale, C., Broyd, S. J., Chye, Y., Suo, C., Schira, M. M., Galettis, P., Martin, J. H., Yücel, M., & Solowij, N. (2018) · Cannabis and Cannabinoid Research · doi:10.1089/can.2017.0047 · Cited by 82
Effects of cannabidiol in males and females in two different rat models of depression
Shbiro, L., Hen-Shoval, D., Hazut, N., Rapps, K., Dar, S., Zalsman, G., Mechoulam, R., Weller, A., & Shoval, G. (2018) · Physiology & Behavior · doi:10.1016/j.physbeh.2018.12.019 · Cited by 76
O’Neill, A., Wilson, R. P., Blest‐Hopley, G., Annibale, L., Colizzi, M., Brammer, M. J., Giampietro, V., & Bhattacharyya, S. (2020) · Psychological Medicine · doi:10.1017/s0033291719003519 · Cited by 77
Factors Moderating the Association between Cannabis Use and Psychosis Risk: A Systematic Review
van der Steur, S. J., Batalla, A., & Bossong, M. G. (2020) · Brain Sciences · doi:10.3390/brainsci10020097 · Cited by 78
Self-citationFischer, B., Russell, C., Rehm, J. T., & Leece, P. (2018) · Journal of Public Health · doi:10.1093/pubmed/fdy090 · Cited by 77
The effects of cannabidiol on persecutory ideation and anxiety in a high trait paranoid group
Hundal, H., Lister, R., Evans, N., Antley, A., Englund, A., Murray, R. M., Freeman, D. H., & Morrison, P. D. (2017) · Journal of Psychopharmacology · doi:10.1177/0269881117737400 · Cited by 70
Cannabis use and sleep: Expectations, outcomes, and the role of age
Winiger, E. A., Hitchcock, L. N., Bryan, A. D., & Bidwell, L. C. (2020) · Addictive Behaviors · doi:10.1016/j.addbeh.2020.106642 · Cited by 72
The Association between Cannabis Product Characteristics and Symptom Relief
Stith, S. S., Vigil, J. M., Brockelman, F., Keeling, K., & Hall, B. (2019) · Scientific Reports · doi:10.1038/s41598-019-39462-1 · Cited by 68
The Impact of Cannabidiol on Human Brain Function: A Systematic Review
Batalla, A., Bos, J., Postma, A., & Bossong, M. G. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.618184 · Cited by 75
Self-citationCharacterisation of cannabinoid composition in a diverse Cannabis sativa L. germplasm collection
Welling, M. T., Liu, L., Shapter, T., Raymond, C. A., & King, G. J. W. (2015) · Euphytica · doi:10.1007/s10681-015-1585-y · Cited by 64
Atsmon, J., Heffetz, D., Deutsch, L., Deutsch, F., & Sacks, H. (2017) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.408 · Cited by 69
Emerging Role of (Endo)Cannabinoids in Migraine
Leimuranta, P., Khiroug, L. S., & Giniatullin, R. A. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00420 · Cited by 67
Is cannabidiol the ideal drug to treat non-motor Parkinson’s disease symptoms?
Crippa, J. A. S., Hallak, J. E. C., Zuardi, A. W., Guimarães, F. S., Tumas, V., & SANTOS, R. G. D. (2019) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-019-00982-6 · Cited by 66
Aran, A. A., & Cayam-Rand, D. (2020) · Rambam Maimonides Medical Journal · doi:10.5041/rmmj.10386 · Cited by 70
Exploring the use of cannabis as a substitute for prescription drugs in a convenience sample
Kvamme, S. L., Pedersen, M. M., Thomsen, K. R., & Thylstrup, B. (2021) · Harm Reduction Journal · doi:10.1186/s12954-021-00520-5 · Cited by 62
Szkudlarek, H. J., Desai, S. J., Renard, J., Pereira, B. J. G., Norris, C., Jobson, C. E. L., Rajakumar, N., Allman, B. L., & Laviolette, S. R. (2018) · Neuropsychopharmacology · doi:10.1038/s41386-018-0282-7 · Cited by 66
The neuropharmacology of cannabinoid receptor ligands in central signaling pathways
Brunt, T. M., & Bossong, M. G. (2020) · European Journal of Neuroscience · doi:10.1111/ejn.14982 · Cited by 67
Self-citationThe Behavioral Sequelae of Cannabis Use in Healthy People: A Systematic Review
Sorkhou, M., Bedder, R. H., & George, T. P. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.630247 · Cited by 61
A scoping review of the use of cannabidiol in psychiatric disorders
Kirkland, A. E., Fadus, M. C., Gruber, S. A., Gray, K. M., Wilens, T. E., & Squeglia, L. M. (2021) · Psychiatry Research · doi:10.1016/j.psychres.2021.114347 · Cited by 63
Marijuana use and viral suppression in persons receiving medical care for HIV-infection
Okafor, C. N., Zhou, Z., Burrell, L. E., Kelso, N. E., Whitehead, N. E., Harman, J. S., Cook, C. L., & Cook, R. L. (2016) · The American Journal of Drug and Alcohol Abuse · doi:10.1080/00952990.2016.1191505 · Cited by 58
Cannabinoids and Schizophrenia: Risks and Therapeutic Potential
Manseau, M. W., & GOFF, D. C. (2015) · Neurotherapeutics · doi:10.1007/s13311-015-0382-6 · Cited by 60
Farquharson, S., Brouillette, C. R., Smith, W., & Shende, C. S. (2019) · Frontiers in Chemistry · doi:10.3389/fchem.2019.00706 · Cited by 56
Understanding disparities in viral suppression among Black MSM living with HIV in Atlanta Georgia
Sullivan, P. S., Knox, J., Jones, J., Taussig, J., Valentine Graves, M., Millett, G., Luisi, N., Hall, E., Sanchez, T. H., Del Rio, C., et al. (2021) · Journal of the International AIDS Society · doi:10.1002/jia2.25689 · Cited by 62
de Ternay, J., Naassïla, M., Nourredine, M., Louvet, A., Bailly, F., Sescousse, G., Maurage, P., Cottencin, O., Carrieri, P., & Rolland, B. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00627 · Cited by 52
Potency and Therapeutic THC and CBD Ratios: U.S. Cannabis Markets Overshoot
Pennypacker, S. D., Cunnane, K., Cash, M. C., & Romero-Sandoval, E. A. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.921493 · Cited by 58
Ricci, V., Ceci, F., Carlo, F. D., Muzio, I. D., Ciavoni, L., Santangelo, M., Salvo, G. D., Pettorruso, M., Martinotti, G., & Maina, G. (2023) · Psychiatry Research · doi:10.1016/j.psychres.2023.115053 · Cited by 52
Cannabis use and mood disorders: a systematic review
Sorkhou, M., Dent, E. L., & George, T. P. (2024) · Frontiers in Public Health · doi:10.3389/fpubh.2024.1346207 · Cited by 61
Brzozowska, N., Li, K. M., Wang, X., Booth, J., Stuart, J. M., McGregor, I. S., & Arnold, J. C. (2016) · PeerJ · doi:10.7717/peerj.2081 · Cited by 49
CBD and THC: Do They Complement Each Other Like Yin and Yang?
Pennypacker, S. D., & Romero-Sandoval, E. A. (2020) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2469 · Cited by 54
Boehnke, K. F., Scott, J. R., Litinas, E., Sisley, S., Williams, D. A., & Clauw, D. J. (2019) · Journal of Pain · doi:10.1016/j.jpain.2019.09.006 · Cited by 47
Cannabidiol for the Treatment of Brain Disorders: Therapeutic Potential and Routes of Administration
Yau, G. T. Y., Tai, W., Arnold, J. C., Chan, H., & Kwok, P. C. L. (2023) · Pharmaceutical Research · doi:10.1007/s11095-023-03469-1 · Cited by 48
Kolla, N. J., & Mishra, A. (2018) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2018.00041 · Cited by 46
Early psychosis research at Orygen, The National Centre of Excellence in Youth Mental Health
Cotton, S., Filia, K., Ratheesh, A., Pennell, K., Goldstone, S. D., & McGorry, P. D. (2015) · Social Psychiatry and Psychiatric Epidemiology · doi:10.1007/s00127-015-1140-0 · Cited by 47
MK-801-induced deficits in social recognition in rats
Deiana, S., Watanabe, A., Yamasaki, Y., Amada, N., Kikuchi, T., Stott, C. G., & Riedel, G. (2015) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000178 · Cited by 49
Thomsen, K. R., Lindholst, C., Thylstrup, B., Kvamme, S. L., Reitzel, L. A., Worm‐Leonhard, M., Englund, A., Freeman, T. P., & Hesse, M. (2019) · Experimental and Clinical Psychopharmacology · doi:10.1037/pha0000303 · Cited by 44
Hammond, D. G., & Goodman, S. E. (2020) · Cannabis and Cannabinoid Research · doi:10.1089/can.2020.0092 · Cited by 44
Viudez‐Martínez, A., García‐Gutiérrez, M. S., & Manzanares, J. (2018) · Journal of Psychopharmacology · doi:10.1177/0269881118805495 · Cited by 43
Ma, H., Xu, F., Liu, C., & Seeram, N. P. (2020) · Cannabis and Cannabinoid Research · doi:10.1089/can.2020.0025 · Cited by 42
Prospects for the Use of Cannabinoids in Psychiatric Disorders
Graczyk, M., Łukowicz, M., & Dzierżanowski, T. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.620073 · Cited by 45
Pros and Cons of Medical Cannabis use by People with Chronic Brain Disorders
Suryadevara, U., Bruijnzeel, D. M., Nuthi, M., Jagnarine, D. A., Tandon, R., & Bruijnzeel, A. W. (2017) · Current Neuropharmacology · doi:10.2174/1570159x14666161101095325 · Cited by 43
The acute effects of cannabis on human executive function
Oomen, P. P., van Hell, H. H., & Bossong, M. G. (2018) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000426 · Cited by 45
Self-citationBuprenorphine–cannabis interaction in patients undergoing opioid maintenance therapy
Vierke, C., Marxen, B., Böettcher, M., Hiemke, C., & Havemann‐Reinecke, U. (2020) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-019-01091-0 · Cited by 40
Hosseini, A., McLachlan, A. J., & Lickliter, J. D. (2020) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14617 · Cited by 44
Fischer, B., Kuganesan, S., Gallassi, A. D., Malcher‐Lopes, R., van den Brink, W., & Wood, E. (2015) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2015.09.005 · Cited by 41
Hudson, R., Rushlow, W. J., & Laviolette, S. R. (2017) · Psychopharmacology · doi:10.1007/s00213-017-4766-7 · Cited by 40
Schnapp, A., Harel, M., Cayam-Rand, D., Cassuto, H., Polyansky, L., & Aran, A. A. (2022) · Biomedicines · doi:10.3390/biomedicines10071685 · Cited by 42
Todd, S. M., Zhou, C., Clarke, D. J., Chohan, T. W., Bahceci, D., & Arnold, J. C. (2017) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2016.12.004 · Cited by 40
Ragazzi, T. C. C., Shuhama, R., Menezes, P. R., & Del‐Ben, C. M. (2018) · Early Intervention in Psychiatry · doi:10.1111/eip.12693 · Cited by 40
Cannabidiol induces autophagy and improves neuronal health associated with SIRT1 mediated longevity
Wang, Z., Zheng, P., Chen, X., Xie, Y., Weston–Green, K., Solowij, N., Chew, Y. L., & Huang, X. (2022) · GeroScience · doi:10.1007/s11357-022-00559-7 · Cited by 41
New vistas on cannabis use disorder
Melis, M., Frau, R., Kalivas, P. W., Spencer, S. M., Chioma, V. C., Zamberletti, E., Rubino, T., & Parolaro, D. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.03.033 · Cited by 38
Bahji, A., Meyyappan, A. C., & Hawken, E. R. (2020) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2020.07.030 · Cited by 39
The Management of Cancer Symptoms and Treatment-Induced Side Effects With Cannabis or Cannabinoids
Sexton, M., Garcia, J. M., Jatoi, A., Clark, C. S., & Wallace, M. S. (2021) · JNCI Monographs · doi:10.1093/jncimonographs/lgab011 · Cited by 36
Silveira, M. M., Arnold, J. C., Laviolette, S. R., Hillard, C. J., Celorrio, M., Aymerich, M. S., & Adams, W. K. (2016) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.09.007 · Cited by 38
Metadata
- Authors
- Iseger, T. A., & Bossong, M. G.
- Affiliations
- King's College London (GB)
- Corresponding author
- Bossong, Matthijs G.
- Venue
- Schizophrenia Research
- Publisher
- Elsevier BV
- Published
- 2015-03
- Volume
- 162
- Issue
- 1-3
- Pages
- 153-161
- ISSN
- 0920-9964 (ISSN-L)
- OpenAlex
- W2135363891
- Cited by
- 261
- References
- 81
- Citations by year
- 2026: 3 · 2025: 18 · 2024: 16 · 2023: 15 · 2022: 19 · 2021: 30 · 2020: 32 · 2019: 27 · 2018: 36 · 2017: 29 · 2016: 22 · 2015: 13
- FWCI
- 4.18
- Type
- journal article
- Language
- en
- Open access
- green
- dspace.library.uu.nl
- Licence
- Locations
- Schizophrenia Research (publishedVersion)
- PubMed (publishedVersion)
- Utrecht University Repository (Utrecht University) (submittedVersion, other-oa)
- Research Portal (King's College London) (submittedVersion)
- Utrecht University Repository (Utrecht University) (submittedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Keywords
- cannabidiol
- MeSH terms
- Brain, Cannabidiol, Humans, Psychotic Disorders, Antipsychotic Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
